Clear Rock Advisors LLC Raises Holdings in Zoetis Inc. (NYSE:ZTS)

Clear Rock Advisors LLC increased its position in Zoetis Inc. (NYSE:ZTS) by 2.4% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 15,113 shares of the company’s stock after purchasing an additional 356 shares during the period. Zoetis accounts for about 1.1% of Clear Rock Advisors LLC’s holdings, making the stock its 29th biggest holding. Clear Rock Advisors LLC’s holdings in Zoetis were worth $2,557,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Blue Bell Private Wealth Management LLC grew its position in shares of Zoetis by 222.5% during the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after acquiring an additional 89 shares during the last quarter. Webster Bank N. A. raised its holdings in shares of Zoetis by 89.1% in the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after buying an additional 82 shares during the last quarter. Independence Bank of Kentucky boosted its stake in shares of Zoetis by 371.4% during the fourth quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock worth $33,000 after buying an additional 130 shares during the period. Private Wealth Management Group LLC purchased a new position in shares of Zoetis during the fourth quarter worth about $33,000. Finally, Gladius Capital Management LP acquired a new position in Zoetis in the 4th quarter valued at about $40,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Price Performance

ZTS traded down $1.83 during trading on Friday, reaching $180.59. 2,699,619 shares of the stock were exchanged, compared to its average volume of 1,898,130. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.33 and a quick ratio of 1.94. The company has a market capitalization of $82.40 billion, a price-to-earnings ratio of 34.80, a P/E/G ratio of 2.83 and a beta of 0.86. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The business’s 50 day moving average price is $175.44 and its two-hundred day moving average price is $175.72.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, topping the consensus estimate of $1.34 by $0.04. The business had revenue of $2.19 billion for the quarter, compared to analyst estimates of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The business’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.31 EPS. As a group, equities research analysts anticipate that Zoetis Inc. will post 5.76 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 4th. Stockholders of record on Thursday, July 18th will be given a $0.432 dividend. The ex-dividend date of this dividend is Thursday, July 18th. This represents a $1.73 annualized dividend and a dividend yield of 0.96%. Zoetis’s dividend payout ratio is presently 33.14%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on ZTS shares. HSBC lowered their target price on Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. Barclays reduced their target price on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research note on Tuesday, April 23rd. Stifel Nicolaus dropped their price target on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, April 30th. Piper Sandler reaffirmed an “overweight” rating and issued a $195.00 price objective (down previously from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Finally, BTIG Research assumed coverage on Zoetis in a research note on Thursday, July 25th. They set a “buy” rating and a $220.00 target price for the company. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $212.67.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.